Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Sequence specific assignment and determination of OSR1 C-terminal domain structure by NMR.

AlAmri MA, Jeeves M, Mehellou Y.

Biochem Biophys Res Commun. 2019 Apr 30;512(2):338-343. doi: 10.1016/j.bbrc.2019.03.065. Epub 2019 Mar 17.

PMID:
30894278
2.

Phosphotyrosine prodrugs: design, synthesis and anti-STAT3 activity of ISS-610 aryloxy triester phosphoramidate prodrugs.

Miccoli A, Dhiani BA, Mehellou Y.

Medchemcomm. 2018 Nov 7;10(2):200-208. doi: 10.1039/c8md00244d. eCollection 2019 Feb 1.

PMID:
30881608
3.

The ProTide Prodrug Technology: Where Next?

Alanazi AS, James E, Mehellou Y.

ACS Med Chem Lett. 2018 Dec 20;10(1):2-5. doi: 10.1021/acsmedchemlett.8b00586. eCollection 2019 Jan 10.

PMID:
30655934
4.

Chemical Strategies for Activating PINK1, a Protein Kinase Mutated in Parkinson's Disease.

Lambourne OA, Mehellou Y.

Chembiochem. 2018 Dec 4;19(23):2433-2437. doi: 10.1002/cbic.201800497. Epub 2018 Nov 7.

PMID:
30248222
5.

C-terminal phosphorylation of SPAK and OSR1 kinases promotes their binding and activation by the scaffolding protein MO25.

Mehellou Y, Alamri MA, Dhiani BA, Kadri H.

Biochem Biophys Res Commun. 2018 Sep 10;503(3):1868-1873. doi: 10.1016/j.bbrc.2018.07.128. Epub 2018 Jul 27.

PMID:
30060950
6.

The Photosensitising Clinical Agent Verteporfin Is an Inhibitor of SPAK and OSR1 Kinases.

AlAmri MA, Kadri H, Alderwick LJ, Jeeves M, Mehellou Y.

Chembiochem. 2018 Oct 4;19(19):2072-2080. doi: 10.1002/cbic.201800272. Epub 2018 Aug 22.

PMID:
29999233
7.

Niclosamide, a Drug with Many (Re)purposes.

Kadri H, Lambourne OA, Mehellou Y.

ChemMedChem. 2018 Jun 6;13(11):1088-1091. doi: 10.1002/cmdc.201800100. Epub 2018 May 8.

PMID:
29603892
8.

Synthesis and Biological Evaluation of ( E)-4-Hydroxy-3-methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 T-Cell Immune Responses.

Davey MS, Malde R, Mykura RC, Baker AT, Taher TE, Le Duff CS, Willcox BE, Mehellou Y.

J Med Chem. 2018 Mar 8;61(5):2111-2117. doi: 10.1021/acs.jmedchem.7b01824. Epub 2018 Feb 23.

9.

The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1.

Barini E, Miccoli A, Tinarelli F, Mulholland K, Kadri H, Khanim F, Stojanovski L, Read KD, Burness K, Blow JJ, Mehellou Y, Muqit MMK.

Chembiochem. 2018 Mar 2;19(5):425-429. doi: 10.1002/cbic.201700500. Epub 2018 Jan 24.

10.

WNK Signaling Inhibitors as Potential Antihypertensive Drugs.

AlAmri MA, Kadri H, Dhiani BA, Mahmood S, Elzwawi A, Mehellou Y.

ChemMedChem. 2017 Oct 20;12(20):1677-1686. doi: 10.1002/cmdc.201700425. Epub 2017 Sep 26. Review.

PMID:
28881465
11.

BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain.

Salim M, Knowles TJ, Baker AT, Davey MS, Jeeves M, Sridhar P, Wilkie J, Willcox CR, Kadri H, Taher TE, Vantourout P, Hayday A, Mehellou Y, Mohammed F, Willcox BE.

ACS Chem Biol. 2017 Oct 20;12(10):2631-2643. doi: 10.1021/acschembio.7b00694. Epub 2017 Sep 14.

12.

The ProTide Prodrug Technology: From the Concept to the Clinic.

Mehellou Y, Rattan HS, Balzarini J.

J Med Chem. 2018 Mar 22;61(6):2211-2226. doi: 10.1021/acs.jmedchem.7b00734. Epub 2017 Aug 24. Review.

PMID:
28792763
13.

Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains.

AlAmri MA, Kadri H, Alderwick LJ, Simpkins NS, Mehellou Y.

ChemMedChem. 2017 May 9;12(9):639-645. doi: 10.1002/cmdc.201700077. Epub 2017 Apr 12.

PMID:
28371477
14.

Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization.

Osgerby L, Lai YC, Thornton PJ, Amalfitano J, Le Duff CS, Jabeen I, Kadri H, Miccoli A, Tucker JHR, Muqit MMK, Mehellou Y.

J Med Chem. 2017 Apr 27;60(8):3518-3524. doi: 10.1021/acs.jmedchem.6b01897. Epub 2017 Mar 28.

15.

Towards the Development of Small-Molecule MO25 Binders as Potential Indirect SPAK/OSR1 Kinase Inhibitors.

Kadri H, Alamri MA, Navratilova IH, Alderwick LJ, Simpkins NS, Mehellou Y.

Chembiochem. 2017 Mar 2;18(5):460-465. doi: 10.1002/cbic.201600620. Epub 2017 Jan 30.

PMID:
28004876
16.

Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.

Thornton PJ, Kadri H, Miccoli A, Mehellou Y.

J Med Chem. 2016 Dec 8;59(23):10400-10410. Epub 2016 Sep 8. Review.

PMID:
27559756
17.

The ProTides Boom.

Mehellou Y.

ChemMedChem. 2016 Jun 6;11(11):1114-6. doi: 10.1002/cmdc.201600156. Epub 2016 May 9.

PMID:
27159529
18.

Organometallic nucleoside analogues with ferrocenyl linker groups: synthesis and cancer cell line studies.

Nguyen HV, Sallustrau A, Balzarini J, Bedford MR, Eden JC, Georgousi N, Hodges NJ, Kedge J, Mehellou Y, Tselepis C, Tucker JH.

J Med Chem. 2014 Jul 10;57(13):5817-22. doi: 10.1021/jm500246h. Epub 2014 Jun 20.

PMID:
24905419
19.

The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction.

Ohta A, Schumacher FR, Mehellou Y, Johnson C, Knebel A, Macartney TJ, Wood NT, Alessi DR, Kurz T.

Biochem J. 2013 Apr 1;451(1):111-22. doi: 10.1042/BJ20121903.

20.

Structural insights into the activation of MST3 by MO25.

Mehellou Y, Alessi DR, Macartney TJ, Szklarz M, Knapp S, Elkins JM.

Biochem Biophys Res Commun. 2013 Feb 15;431(3):604-9. doi: 10.1016/j.bbrc.2012.12.113. Epub 2013 Jan 4.

21.

Synthesis of pdCpAs and transfer RNAs activated with thiothreonine and derivatives.

Chen S, Fahmi NE, Nangreave RC, Mehellou Y, Hecht SM.

Bioorg Med Chem. 2012 Apr 15;20(8):2679-89. doi: 10.1016/j.bmc.2012.02.024. Epub 2012 Feb 15.

22.

SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation.

Thastrup JO, Rafiqi FH, Vitari AC, Pozo-Guisado E, Deak M, Mehellou Y, Alessi DR.

Biochem J. 2012 Jan 1;441(1):325-37. doi: 10.1042/BJ20111879.

23.

MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases.

Filippi BM, de los Heros P, Mehellou Y, Navratilova I, Gourlay R, Deak M, Plater L, Toth R, Zeqiraj E, Alessi DR.

EMBO J. 2011 May 4;30(9):1730-41. doi: 10.1038/emboj.2011.78. Epub 2011 Mar 18.

24.

Phosphoramidate prodrugs deliver with potency against hepatitis C virus.

Mehellou Y.

ChemMedChem. 2010 Nov 8;5(11):1841-2. doi: 10.1002/cmdc.201000310. No abstract available.

PMID:
20865770
25.

Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism.

Mehellou Y, Valente R, Mottram H, Walsby E, Mills KI, Balzarini J, McGuigan C.

Bioorg Med Chem. 2010 Apr 1;18(7):2439-46. doi: 10.1016/j.bmc.2010.02.059. Epub 2010 Mar 1.

PMID:
20299228
26.

The design, synthesis and antiviral evaluation of a series of 5-trimethylsilyl-1-beta-D-(arabinofuranosyl)uracil phosphoramidate ProTides.

Mehellou Y, Balzarini J, McGuigan C.

Antivir Chem Chemother. 2010 Mar 9;20(4):153-60. doi: 10.3851/IMP1476.

PMID:
20231780
27.

Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

Mehellou Y, De Clercq E.

J Med Chem. 2010 Jan 28;53(2):521-38. doi: 10.1021/jm900492g. Review. No abstract available.

PMID:
19785437
28.

Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells.

Mehellou Y, Balzarini J, McGuigan C.

ChemMedChem. 2009 Nov;4(11):1779-91. doi: 10.1002/cmdc.200900289. Review.

PMID:
19760699
29.

An investigation into the anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U) and 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.

Mehellou Y, Balzarini J, McGuigan C.

Org Biomol Chem. 2009 Jun 21;7(12):2548-53. doi: 10.1039/b904276h. Epub 2009 Apr 30.

PMID:
19503928
30.

Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.

Mehellou Y, McGuigan C, Brancale A, Balzarini J.

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3666-9. Epub 2007 Apr 22.

PMID:
17485204

Supplemental Content

Loading ...
Support Center